SCF-AE-MNSS-TEMP-0009
SCF Disease Progression Timeline Mapping
Autoimmune Encephalopathy (AE)
Therapeutic Temporal Windows Mapped to SCF Multi-Neurosystems Shock States (MNSS)
Integrated Neuroimmune, Neurocardiac, Neurovascular, Neurometabolic, and Neuroendocrine Shock-State Architecture
Pre-Encephalopathy → Active Autoimmune Encephalopathy → Post-Encephalopathy Neuroimmune Reconstruction
I. SCF AUTOIMMUNE ENCEPHALOPATHY PATHOGENESIS CASCADE
Etiopathogenic Core
Genetic Susceptibility
↓
Immune Trigger
(Infection, Tumor, Vaccine Response, Molecular Mimicry, Systemic Autoimmunity)
↓
Peripheral Immune Activation
↓
Autoantibody Generation
↓
BBB Dysfunction
↓
CNS Immune Infiltration
↓
Microglial Activation
↓
Astrocytic Activation
↓
Synaptic Receptor Dysfunction
↓
Neurotransmitter Circuit Failure
↓
Neuroimmune Amplification
↓
Connectomic Collapse
↓
Autoimmune Encephalopathy
↓
Neuroaxonal Injury
↓
Post-Autoimmune Neurocognitive Syndrome
II. MASTER TEMPORAL PROGRESSION MATRIX
SCF Phase | Temporal Window | Dominant Shock State | Clinical Stage | Reversibility |
MNSS-0 | Months–Years | Immune Homeostasis | No CNS disease | Very High |
MNSS-IA | Weeks–Months | Autoimmune Priming | Silent autoimmunity | Very High |
MNSS-IB | Days–Weeks | Neuroimmune Propagation | Early cognitive symptoms | Very High |
MNSS-II | Days Before Overt AE | Neurovascular-Neuroglial Shock | Prodromal AE | High |
MNSS-IIIA | Hours–Days | Early Autoimmune Encephalopathy | Mild-Moderate AE | High |
MNSS-IIIB | Days–Weeks | Established AE | Moderate-Severe AE | Moderate |
MNSS-IV | Hours–Days | Global Multi-Neurosystems Shock | Fulminant AE | Limited |
MNSS-R1 | Days–Weeks | Immune Resolution | Recovery Initiation | High |
MNSS-R2 | Weeks–Months | Connectomic Reconstruction | Functional Recovery | Moderate–High |
MNSS-R3 | Months–Years | Neuroadaptive Compensation | Post-AE Syndrome | Variable |
III. PRE-ENCEPHALOPATHY WINDOW 1
MNSS-IA — AUTOIMMUNE PRIMING STATE
Temporal Window
Weeks to Months Before Neurologic Symptoms
Dominant SCF Shock States
- Neuroimmune Shock (NIS-1)
- Neuroendocrine Shock (NES-1)
SCF Biomarker Panel
Domain | Biomarker | Baseline | Alert Threshold |
Neuroimmune | IL-6 | <2 pg/mL | >10 pg/mL |
Neuroimmune | TNF-α | <5 pg/mL | >10 pg/mL |
Neuroimmune | IFN-γ | Normal | Elevated |
Neuroimmune | CXCL13 | <20 pg/mL | >50 pg/mL |
Neuroimmune | HMGB1 | Low | Elevated |
Autoimmune | NMDAR-IgG | Negative | Positive |
Autoimmune | LGI1-IgG | Negative | Positive |
Autoimmune | CASPR2-IgG | Negative | Positive |
Autoimmune | AMPAR-IgG | Negative | Positive |
Neuroendocrine | Cortisol Rhythm | Normal | Flattened |
Neuroendocrine | DHEA-S | Normal | ↓15% |
Neuroendocrine | Melatonin | Normal | Reduced |
Clinical Manifestations
- Fatigue
- Sleep disruption
- Anxiety
- Mild cognitive slowing
- Subjective memory decline
Therapeutic Objective
Prevent CNS immune sensitization and BBB vulnerability.
IV. PRE-ENCEPHALOPATHY WINDOW 2
MNSS-IB — NEUROIMMUNE PROPAGATION PHASE
Temporal Window
Days to Weeks Before Overt Disease
Dominant SCF Shock States
- Neuroimmune Shock (NIS-2)
- Neurovascular Shock (NVS-1)
- Neurocardiac Shock (NCS-1)
SCF Biomarker Panel
Domain | Biomarker | Alert Threshold |
Neuroimmune | IL-6 | >15 pg/mL |
Neuroimmune | TNF-α | >15 pg/mL |
Neuroimmune | CXCL13 | >100 pg/mL |
Neuroimmune | HMGB1 | >5 ng/mL |
Neurovascular | MMP-9 | >250 ng/mL |
Neurovascular | ICAM-1 | Elevated |
Neurovascular | VCAM-1 | Elevated |
Neurovascular | Albumin Quotient | Rising |
Neurocardiac | SDNN | <90 ms |
Neurocardiac | RMSSD | <25 ms |
Neurocardiac | LF/HF Ratio | >3 |
Clinical Manifestations
- Memory lapses
- Mood instability
- Executive dysfunction
- Reduced concentration
Therapeutic Objective
Prevent BBB penetration and CNS immune invasion.
V. PRODROMAL AUTOIMMUNE ENCEPHALOPATHY
MNSS-II — NEUROVASCULAR-NEUROGLIAL SHOCK
Temporal Window
Days Before Overt AE
Dominant SCF Shock States
- Neurovascular Shock (NVS-2)
- Neuroglial Shock (NGS-1)
- Neurometabolic Shock (NMS-1)
SCF Biomarker Panel
Domain | Biomarker | Threshold |
Neurovascular | MMP-9 | >300 ng/mL |
Neurovascular | Albumin Quotient | Elevated |
Neurovascular | S100B | >0.15 ng/mL |
Neuroglial | GFAP | >150 pg/mL |
Neuroglial | YKL-40 | >100 ng/mL |
Neuroglial | sTREM2 | Elevated |
Neurometabolic | Lactate | >2 mmol/L |
Neurometabolic | ATP Production | ↓20% |
Neurometabolic | cf-mtDNA | Elevated |
Clinical Manifestations
- Personality changes
- Mild psychosis
- Executive dysfunction
- Episodic confusion
Therapeutic Objective
Prevent synaptic receptor disruption and network destabilization.
VI. EARLY AUTOIMMUNE ENCEPHALOPATHY
MNSS-IIIA
Temporal Window
Hours–Days Following Clinical Recognition
Dominant SCF Shock States
- Neuroimmune Shock (NIS-3)
- Neuroglial Shock (NGS-2)
- Neuroendocrine Shock (NES-2)
SCF Biomarker Panel
Neuroimmune Shock
Biomarker | Threshold |
IL-6 | >20 pg/mL |
TNF-α | >20 pg/mL |
CXCL13 | >150 pg/mL |
IFN-γ | Elevated |
Autoimmune Drivers
Biomarker | Threshold |
NMDAR-IgG | Rising titer |
LGI1-IgG | Rising titer |
CASPR2-IgG | Rising titer |
AMPAR-IgG | Rising titer |
GABA-BR-IgG | Rising titer |
Neuroglial Shock
Biomarker | Threshold |
GFAP | >250 pg/mL |
S100B | >0.20 ng/mL |
YKL-40 | >150 ng/mL |
Neuroendocrine Shock
Biomarker | Threshold |
Cortisol | Elevated |
ACTH | Elevated |
Melatonin | Suppressed |
Clinical Manifestations
- Memory impairment
- Psychiatric symptoms
- Confusion
- Early seizures
- Sleep-wake disruption
Therapeutic Objective
Preserve synaptic integrity and prevent connectomic collapse.
VII. ESTABLISHED AUTOIMMUNE ENCEPHALOPATHY
MNSS-IIIB
Temporal Window
Days–Weeks
Dominant SCF Shock States
- Neuroaxonal Shock (NAS-1)
- Neurocardiac Shock (NCS-2)
- Neurometabolic Shock (NMS-2)
SCF Biomarker Panel
Neuroaxonal Shock
Biomarker | Threshold |
NfL | >20 pg/mL |
UCH-L1 | Elevated |
Tau | Elevated |
NSE | Elevated |
Neurocardiac Shock
Biomarker | Threshold |
SDNN | <80 ms |
RMSSD | <15 ms |
QTc | Prolonged |
Troponin | Mild elevation |
Neurometabolic Shock
Biomarker | Threshold |
Lactate | >3 mmol/L |
ATP Production | ↓40% |
cf-mtDNA | High |
Clinical Manifestations
- Persistent seizures
- Dysautonomia
- Cognitive deterioration
- Behavioral dysregulation
- Psychosis
Therapeutic Objective
Prevent irreversible neuroaxonal injury and autonomic collapse.
VIII. ACUTE MULTI-NEUROSYSTEMS SHOCK
MNSS-IV
Temporal Window
Hours–Days
Dominant SCF Shock States
- Neuroimmune Shock (NIS-4)
- Neurocardiac Shock (NCS-3)
- Neurovascular Shock (NVS-3)
- Neurometabolic Shock (NMS-3)
- Neuroendocrine Shock (NES-3)
Peak Biomarker Panel
Shock Domain | Peak Biomarkers |
Neuroimmune | IL-6, TNF-α, CXCL13, IFN-γ, HMGB1 |
Neurocardiac | SDNN <50 ms, RMSSD severely reduced, Troponin ↑, NT-proBNP ↑ |
Neurovascular | MMP-9 peak, S100B peak, Albumin Quotient peak |
Neurometabolic | Lactate >4 mmol/L, ATP failure, cf-mtDNA peak |
Neuroendocrine | Cortisol dysregulation, ACTH dysregulation, melatonin suppression |
Neuroglial | GFAP peak, YKL-40 peak |
Neuroaxonal | NfL peak, Tau peak, UCH-L1 peak |
Clinical Manifestations
- Refractory seizures
- Status epilepticus
- Catatonia
- Coma
- Severe psychosis
- Autonomic instability
Therapeutic Objective
Life preservation and neuronal salvage.
IX. POST-ENCEPHALOPATHY RECOVERY WINDOW
MNSS-R1 — IMMUNE RESOLUTION
Temporal Window
Days–Weeks
Recovery Biomarker Panel
Domain | Biomarker Trend |
Neuroimmune | IL-6 ↓, TNF-α ↓, CXCL13 ↓ |
Neurocardiac | SDNN ↑, RMSSD ↑ |
Neurovascular | MMP-9 ↓ |
Neuroglial | GFAP ↓ |
Neuroaxonal | NfL stabilization |
Neuroendocrine | Cortisol normalization |
Therapeutic Objective
Suppress residual neuroinflammation and relapse signaling.
X. CONNECTOMIC RECONSTRUCTION WINDOW
MNSS-R2
Temporal Window
Weeks–Months
Reconstruction Biomarker Panel
Domain | Desired Trend |
Neuroimmune | Autoantibody titers ↓ |
Neuroglial | GFAP ↓ |
Neuroaxonal | NfL ↓ |
Connectomic | qEEG Connectivity ↑ |
Connectomic | DTI Fractional Anisotropy ↑ |
Neurocardiac | HRV SDNN ↑ |
Neuroendocrine | Cortisol rhythm restoration |
Therapeutic Objective
Restore cognitive, autonomic, and limbic network function.
XI. POST-AUTOIMMUNE ENCEPHALOPATHY SYNDROME
MNSS-R3
Temporal Window
Months–Years
Persistent Risk Biomarker Panel
Shock Domain | Persistent Biomarkers |
Neuroimmune | CXCL13, HMGB1, IL-6 |
Neurocardiac | SDNN suppression, LF/HF elevation |
Neurovascular | MMP-9 elevation |
Neurometabolic | Mitochondrial dysfunction markers |
Neuroendocrine | Cortisol rhythm abnormalities |
Neuroglial | GFAP elevation |
Neuroaxonal | NfL, Tau |
Connectomic | Persistent qEEG dysconnectivity |
Autoimmune | Persistent low-titer autoantibodies |
Clinical Manifestations
- Memory impairment
- Executive dysfunction
- Chronic fatigue
- Dysautonomia
- Mood disorders
- Relapse susceptibility
XII. MASTER SCF AUTOIMMUNE ENCEPHALOPATHY BIOMARKER MATRIX
SCF Phase | Neuroimmune Shock | Neurocardiac Shock | Neurovascular Shock | Neurometabolic Shock | Neuroendocrine Shock |
MNSS-IA | IL-6, CXCL13 | SDNN ↓ | ICAM-1 ↑ | ATP ↓ | Cortisol ↑ |
MNSS-IB | HMGB1 ↑ | LF/HF ↑ | MMP-9 ↑ | cf-mtDNA ↑ | DHEA-S ↓ |
MNSS-II | IL-6 ↑↑ | HRV ↓↓ | S100B ↑ | Lactate ↑ | Circadian disruption |
MNSS-IIIA | Cytokine surge | Dysautonomia | BBB dysfunction | ATP loss | HPA activation |
MNSS-IIIB | Persistent inflammation | QTc prolongation | Endothelial dysfunction | Mitochondrial impairment | Melatonin suppression |
MNSS-IV | Peak cytokines | Severe autonomic collapse | Peak BBB injury | Peak metabolic failure | HPA collapse |
MNSS-R1 | Resolution | HRV recovery | BBB repair | ATP recovery | Endocrine recovery |
MNSS-R2 | Low inflammation | SDNN ↑ | Vascular repair | Bioenergetic restoration | Circadian restoration |
MNSS-R3 | Residual inflammation | Persistent dysautonomia | Residual dysfunction | Chronic bioenergetic deficit | Neuroendocrine maladaptation |
XIII. HIGHEST-VALUE THERAPEUTIC WINDOWS
Rank | Window | SCF Phase | Reversibility | Primary Therapeutic Objective |
1 | Autoimmune Priming | MNSS-IA | Very High | Prevent CNS autoimmunity |
2 | Neuroimmune Propagation | MNSS-IB | Very High | Preserve BBB integrity |
3 | Prodromal AE | MNSS-II | High | Prevent receptor dysfunction |
4 | Early AE | MNSS-IIIA | High | Preserve connectomic integrity |
5 | Established AE | MNSS-IIIB | Moderate | Prevent neuroaxonal injury |
6 | Fulminant AE | MNSS-IV | Limited | Preserve life and brain function |
7 | Connectomic Reconstruction | MNSS-R2 | Moderate–High | Restore cognition and autonomics |
XIV. EARLIEST PREDICTIVE SCF BIOMARKER PANEL FOR AUTOIMMUNE ENCEPHALOPATHY
Tier 1 — Autoimmune Drivers
- NMDAR-IgG
- LGI1-IgG
- CASPR2-IgG
- AMPAR-IgG
- GABA-BR-IgG
- DPPX-IgG
Tier 2 — Neuroimmune Predictors
- CXCL13
- IL-6
- TNF-α
- IFN-γ
- HMGB1
Tier 3 — Neurovascular Predictors
- MMP-9
- ICAM-1
- VCAM-1
- Albumin Quotient
Tier 4 — Neuroglial Predictors
- GFAP
- YKL-40
- S100B
- sTREM2
Tier 5 — Neurocardiac Predictors
- HRV SDNN
- RMSSD
- LF/HF Ratio
Tier 6 — Neuroendocrine Predictors
- Cortisol Circadian Rhythm
- DHEA-S
- Melatonin
These biomarker domains collectively identify the highest-value intervention window before overt autoimmune encephalopathy, seizure evolution, receptor-mediated synaptic dysfunction, and connectomic collapse.
MASTER REGISTRY INDEX
- SCF-AE-MNSS-TEMP-0009 — Autoimmune Encephalopathy Disease Progression Timeline Mapping
- SCF-ECCA-AE-0001 — Autoimmune Encephalopathy Module
- SCF-ECCA-AE-BIO-0004 — Autoimmune Encephalopathy Biomarker Panel
- SCF-ECCA-AE-FIH-CTD-0004 — Autoimmune Encephalopathy FIH Clinical Trial Design
- SCF-MNSS-0001 — Multi-Neurosystems Shock State Framework
- SCF-CONNECTOMIC-RECONSTRUCTION-0001 — Neuroimmune Connectomic Reconstruction Framework
- SCF-BIOMARKER-ENDPOINTS-0001 — Biomarker Endpoint Validation Framework
- SCF-PATH-PROT-0001 — SCF Pathophysiology Protocol
- SCF-ACU-NEURO-ATLAS-0001 — SCF Neural Mapping Schema